Showing results (281-290 of 294) with videos related to

Sort By:
Pageof 30
NPJ Vaccines|February 17, 2024
Protective efficacy of a Zika purified inactivated virus vaccine candidate during pregnancy in marmosetsIn-Jeong Kim, Olga Gonzalez, Michael P Tighe, et al.
The New England Journal of Medicine|January 18, 2023
Bivalent Omicron BA.1-Adapted BNT162b2 Booster in Adults Older than 55 YearsPatricia Winokur, Juleen Gayed, David Fitz-Patrick, et al.
The Lancet. Infectious Diseases|July 4, 2020
Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trialKathryn E Stephenson, Chen Sabrina Tan, Stephen R Walsh, et al.
Nature|June 30, 2016
Vaccine protection against Zika virus from BrazilRafael A Larocca, Peter Abbink, Jean Pierre S Peron, et al.
The New England Journal of Medicine|September 15, 2021
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 MonthsStephen J Thomas, Edson D Moreira, Nicholas Kitchin, et al.
The Lancet. Infectious Diseases|June 30, 2023
Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trialMichael A Koren, Leyi Lin, Kenneth H Eckels, et al.
Plos Neglected Tropical Diseases|April 28, 2025
Proceedings of the second annual dengue endgame summit: A call to actionCéline S C Hardy, Lauren E Bahr, Alan L Rothman, et al.
Lancet (London, England)|December 9, 2017
Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trialsKayvon Modjarrad, Leyi Lin, Sarah L George, et al.
NPJ Vaccines|January 28, 2022
Efficacy of an inactivated Zika vaccine against virus infection during pregnancy in mice and marmosetsIn-Jeong Kim, Paula A Lanthier, Madeline J Clark, et al.
The Lancet. Infectious Diseases|July 29, 2019
Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trialKayvon Modjarrad, Christine C Roberts, Kristin T Mills, et al.
Pageof 30